Send
Print
Raysonho @ Open Grid Scheduler / Grid Engine
On a per-share basis, diluted earnings were $5.51 compared to $5.63 in 2019. The company's revenue for the period rose by 0.6 per cent to $82.584 billion.
J&J reported fourth-quarter net profit of $1.738 billion, down 2.3 times from a year ago. On a per-share basis, the company's diluted earnings were $0.65 compared with $1.5 a year earlier. The company's October-December revenue rose 8.3% year on year to $22.475 billion. Analysts expected quarterly revenue of $21.69 billion.
The company also said it expected sales in 2021 in the range of $90.5 billion to $91.7 billion. Adjusted diluted earnings per share are expected to be $9.4-9.6.
"We continue to improve our vaccine product against COVID-19 and look forward to sharing details of Phase 3 trials soon," Alex Gorsky, chairman and CEO, said in a statement.
source: bloomberg.com
J&J reported fourth-quarter net profit of $1.738 billion, down 2.3 times from a year ago. On a per-share basis, the company's diluted earnings were $0.65 compared with $1.5 a year earlier. The company's October-December revenue rose 8.3% year on year to $22.475 billion. Analysts expected quarterly revenue of $21.69 billion.
The company also said it expected sales in 2021 in the range of $90.5 billion to $91.7 billion. Adjusted diluted earnings per share are expected to be $9.4-9.6.
"We continue to improve our vaccine product against COVID-19 and look forward to sharing details of Phase 3 trials soon," Alex Gorsky, chairman and CEO, said in a statement.
source: bloomberg.com
